The GLP-1 receptor agonist liraglutide attenuates atherosclerotic lesion development and enhances plaque stability in an ApoE-/- mouse model

被引：0
|
作者：
Dear, A. E. [1 ]
Gaspari, T. [1 ]
Welungoda, I. [1 ]
Widdop, R. E. [1 ]
Simpson, R. W. [1 ]
机构：
[1] Monash Univ, Melbourne, Vic 3004, Australia
来源：
DIABETOLOGIA | 2012年 / 55卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
780
引用
收藏
页码：S321 / S321
页数：1
相关论文
共 50 条
  • [41] Mzb1 Attenuates Atherosclerotic Plaque Vulnerability in ApoE-/- Mice by Alleviating Apoptosis and Modulating Mitochondrial Function
    Zhu, Guanglang
    Li, Yang
    Gao, Hongxia
    Li, Xu
    Fan, Heyu
    Fan, Longhua
    JOURNAL OF CARDIOVASCULAR TRANSLATIONAL RESEARCH, 2024, 17 (04) : 782 - 794
  • [42] Exendin-4, a GLP-1 Receptor Agonist, Attenuates Prostate Cancer Growth
    Nomiyama, Takashi
    Kawanami, Takako
    Irie, Shinichiro
    Hamaguchi, Yuriko
    Terawaki, Yuichi
    Murase, Kunitaka
    Tsutsumi, Yoko
    Nagaishi, Ryoko
    Tanabe, Makito
    Morinaga, Hidetaka
    Tanaka, Tomoko
    Mizoguchi, Makio
    Nabeshima, Kazuki
    Tanaka, Masatoshi
    Yanase, Toshihiko
    DIABETES, 2014, 63 (11) : 3891 - 3905
  • [43] BONE MARROW DEFICIENCY IN MELANOCORTIN-1 RECEPTOR ENHANCES LEUKOCYTOSIS IN APOE-/- ATHEROSCLEROTIC MICE
    Kadiri, J.
    Tadayon, S.
    Hollmen, M.
    Rinne, P.
    ATHEROSCLEROSIS, 2020, 315 : E23 - E23
  • [44] FNDC5 Attenuates Atherosclerotic Plaque Formation and Regulates PPARa/HO-1 in ApoE-/- Mice
    Zhou, Bo
    Wang, Xiang
    Wang, Yao
    Liu, Danan
    JOURNAL OF VASCULAR RESEARCH, 2023, 60 (03) : 172 - 181
  • [45] Antipsychotic-like effect of GLP-1 agonist liraglutide but not DPP-IV inhibitor sitagliptin in mouse model for psychosis
    Dixit, Tejashree S.
    Sharma, Ajaykumar N.
    Lucot, James B.
    Elased, Khalid M.
    PHYSIOLOGY & BEHAVIOR, 2013, 114 : 38 - 41
  • [46] The New Insulin Sensitizer MSDC-0602K Synergizes with the GLP-1 Receptor Agonist Liraglutide
    Pyles, Kelly D.
    Kamm, Dakota
    Colca, Jerry R.
    McCommis, Kyle S.
    DIABETES, 2020, 69
  • [47] Liraglutide 3mg Therapy of Obesity: GLP-1 Receptor Agonist as new Therapeutic Option
    Aberle, Jens
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2016, 141 (09) : 4 - 10
  • [48] The Dual GLP-1/GIP Receptor Agonist DA4-JC Shows Superior Protective Properties Compared to the GLP-1 Analogue Liraglutide in the APP/PS1 Mouse Model of Alzheimer's Disease
    Maskery, Mark
    Goulding, Elizabeth Mary
    Gengler, Simon
    Melchiorsen, Josefine Ulrikke
    Rosenkilde, Mette Marie
    Holscher, Christian
    AMERICAN JOURNAL OF ALZHEIMERS DISEASE AND OTHER DEMENTIAS, 2020, 35
  • [49] Dapiglutide, a novel dual GLP-1 and GLP-2 receptor agonist, attenuates intestinal insufficiency in a murine model of short bowel
    Reiner, Johannes
    Berlin, Peggy
    Held, Jascha
    Thiery, Johanna
    Skarbaliene, Jolanta
    Griffin, Jonathan
    Russell, Wayne
    Eriksson, Per-Olof
    Berner-Hansen, Mark
    Ehlers, Luise
    Vollmar, Brigitte
    Jaster, Robert
    Witte, Maria
    Lamprecht, Georg
    JOURNAL OF PARENTERAL AND ENTERAL NUTRITION, 2022, 46 (05) : 1107 - 1118
  • [50] Encapsulation in Polymeric Nanoparticles Enhances the Enzymatic Stability and the Permeability of the GLP-1 Analog, Liraglutide, Across a Culture Model of Intestinal Permeability
    Ismail, Ruba
    Bocsik, Alexandra
    Katona, Gabor
    Grof, Ilona
    Deli, Maria A.
    Csoka, Ildiko
    PHARMACEUTICS, 2019, 11 (11)
12345